Mosseri Marlio Charles Buys Nuvectis Pharma Shares
Mosseri Marlio Charles purchased 50,000 shares of Nuvectis Pharma, Inc. at $18.32 each.
Key Points
- Mosseri Marlio Charles bought 50,000 shares of Nuvectis Pharma, Inc. (NVCT) at $18.32 per share, totaling $916,000 on June 30, 2026.
- Shares of NVCT traded near $19.46 on Wednesday, with a market cap of approximately $487.8 million and a 52-week range of $5.55 to $29.28.
- Analysts from HC Wainwright & Co. maintained a buy rating with a $39 price target as of June 22, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mosseri Marlio Charles, an insider at Nuvectis Pharma, Inc. (NasdaqCM: NVCT), purchased 50,000 shares of the company on June 30, 2026. The shares were bought at an average price of $18.32, bringing the total transaction value to $916,000. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Nuvectis Pharma, Inc.
On the same day, Ron Bentsur, the Chairman & CEO, also bought 12,500 shares at $20 each. Earlier in June, several other insiders, including Kenneth Hoberman and Juan Sanchez, acquired 35,000 shares each at undisclosed prices.
Nuvectis Pharma, Inc. Stock Down 18.0%
Shares of Nuvectis Pharma traded near $19.46 on Wednesday. The company has a market cap of approximately $487.8 million. It operates with a forward P/E ratio of -19.16, indicating it is not yet profitable. The stock's beta is -0.072, suggesting lower volatility compared to the market. Over the past year, the stock has ranged from a low of $5.55 to a high of $29.28. Nuvectis has a 50-day moving average of $11.73 and a 200-day moving average of $8.51.
$NVCT stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 22, 2026, HC Wainwright & Co. maintained its buy rating for Nuvectis Pharma, setting a price target of $39. The company has a consensus recommendation of 'strong buy' with a mean price target of $29.20 based on five analyst opinions.
About Nuvectis Pharma
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company based in Fort Lee, New Jersey. It focuses on developing precision medicines for oncology, addressing serious conditions with unmet medical needs. The company is currently working on NXP900, a small molecule drug candidate in Phase 1b trials aimed at treating solid tumors by inhibiting specific kinases. Nuvectis was founded in 2020 and is led by CEO Ron Bentsur.
Bottom Line
Insider buying activity at Nuvectis Pharma, including purchases by Mosseri Marlio Charles, signals confidence in the company's prospects. Investors often watch such transactions as potential indicators of future performance, though it's important to note that insider activity is just one of many factors to consider. The company's stock has shown significant volatility, and analysts remain optimistic with strong buy ratings.
Get Nuvectis Pharma, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NVCT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.